Sign up USA
Proactive Investors - Run By Investors For Investors

Esperion Therapeutics top riser on Nasdaq as FDA impressed

The drug is aimed specifically as a supplementary treatment to statin therapy in patients with high cardiovascular disease risk
Esperion Therapeutics top riser on Nasdaq as FDA impressed
Esperion plans to apply for FDA approval for the drug by the first half of 2019

Esperion Therapeutics Inc (NASDAQ:ESPN) was top riser on Nasdaq Monday, with shares up over 48% as it received welcome feedback from the powerful US FDA on its cholesterol-lowering drug candidate.

The regulatory body said the firm's late-stage clinical program would be enough to support approval for the candidate.

The drug is aimed specifically as a supplementary treatment to statin therapy in patients with high cardiovascular disease risk.

Esperion plans to apply for FDA approval by the first half of 2019, with results from a phase 3 trial expected by the second quarter of 2018.

Tim Mayleben, chief executive of the biotech, said: "We are very pleased to have achieved clarity from FDA regarding Esperion’s LDL-C lowering development program.

"Our experienced lipid management team has worked closely with regulatory authorities and our key advisors to achieve this encouraging outcome.

"We continue to believe that bempedoic acid has the potential to provide physicians with a complementary and convenient oral treatment option that’s cost-effective for their patients with hypercholesterolemia who require additional LDL-C lowering.

"We remain focused on completing the global pivotal Phase 3 program for bempedoic acid and reporting top-line results from our long-term safety and tolerability study by Q2 2018 and top-line results from our ongoing Phase 3 LDL-C lowering efficacy studies by mid-2018."

Shares gained 48.2% to stand at $34.58 a pop.

Giles_55af4ddca6481.jpg


Register here to be notified of future PROAC Company articles
View full PROAC profile View Profile

Proactiveinvestors Timeline

Related Articles

E-mail
October 18 2016
Geographical expansion, product innovation and strategic partnerships continue to be well executed, said house broker finnCap
social-media.jpg
February 20 2017
One particular development of note is Cello Pulsar, a social media analytics tool that has, according to the experts, the potential to be a real winner.
Digital marketing
March 28 2017
Michael Karg, Ebiquity’s CEO, said:“We have already made good progress with our growth acceleration plan, which will replicate our service offering across key territories, further strengthening our ability to service global clients.”
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use